Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; published online April 9. https://doi.org/10.1016/S2213-2600(21)00160-0—In this Article, the findings section of the summary should have read, “For the per-protocol population (n=139), the primary outcome occurred in ten (14%) of 70 participants in the usual care group and one (1%) of 69 participants in the budesonide group”. Additionally, in the Summary and Results, the dose of budesonide should have been 400 μg per actuation, to a total dose (two puffs to be taken twice per day) of 1600 μg. These corrections have been made to the online version as of April 14, 2021, and the printed version is correct.

Article InfoPublication History

Published: April 14, 2021

Identification

DOI: https://doi.org/10.1016/S2213-2600(21)00181-8

Copyright

© 2021 Elsevier Ltd. All rights reserved.

ScienceDirectAccess this article on ScienceDirect Linked Articles